1. People's Republic of China Stocks

  2. •

    Healthcare

  3. •

    Drug Manufacturers - General
Hubei Guangji Pharmaceutical Co., Ltd.

Hubei Guangji Pharmaceutical Co., Ltd.

000952.SZ
Hubei Guangji Pharmaceutical Co., Ltd.CN flagShenzhen Stock Exchange
6.59
CNY
-0.08
- -
2.29BMarket Cap

Total Valuation

Hubei Guangji Pharmaceutical Co., Ltd. carries a market capitalization of 2.29B, placing it among publicly traded companies globally. Its enterprise value stands at 2.91B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Market Cap2.29B
Enterprise Value2.91B

Share Statistics

Hubei Guangji Pharmaceutical Co., Ltd. currently has 349.86M shares outstanding.

Shares Outstanding349.86M
Owned by Insiders (%)N/A
Owned by Institutions (%)N/A

Valuation Ratios

The price-to-sales ratio is 3.45, and the price-to-book ratio stands at 4.52.

PE RatioN/A
PS Ratio3.45
PB Ratio4.52
P/TBV Ratio2.88
P/FCF Ratio27.14
P/OCF RatioN/A

Enterprise Valuation

EV / Sales4.64
EV / EBITDAN/A
EV / EBITN/A
EV / FCF21.08

Financial Position

The debt-to-equity ratio is 127.16, indicating elevated leverage, while an interest coverage ratio of -3.03 demonstrates limited ability to service its debt obligations.

Current RatioN/A
Quick Ratio0.35
Debt / Equity127.16
Debt / EBITDA-7.02
Interest Coverage-3.03

Financial Efficiency

Return on Equity (ROE)-43.14
Return on Assets (ROA)-8.69
Return on Invested Capital (ROIC)N/A
Return on Capital Employed (ROCE)N/A
Revenue Per EmployeeN/A
Employee CountN/A
Inventory Turnover1.31

Taxes

Income Tax-5.15M
Effective Tax RateN/A

Stock Price Statistics

Hubei Guangji Pharmaceutical Co., Ltd.'s stock has gained approximately 5.44% over the past 52 weeks. The 50-day moving average sits at 7.14, while the 200-day moving average is 7.34.

Beta (5Y)N/A
52-Week Price Change5.44%
50-Day Moving Average7.14
200-Day Moving Average7.34
Average Volume (20 Days)N/A

Income Statement

Over the trailing twelve months, Hubei Guangji Pharmaceutical Co., Ltd. generated 626.70M in revenue and converted that into -264.16M in net income, yielding earnings per share of -0.81. EBITDA reached -179.43M, while operating income came in at -179.43M.

Revenue626.70M
Gross Profit131.69M
Operating Income-179.43M
Pretax Income-287.02M
Net Income-264.16M
EBITDA-179.43M
EBIT-179.43M
Earnings Per Share (EPS)-0.81

Balance Sheet

Hubei Guangji Pharmaceutical Co., Ltd. holds 519.98M in cash and equivalents against 1.26B in total debt, resulting in a net debt position of 256.37M. Total book value stands at 478.63M, with working capital of -1.49B providing operational flexibility.

Cash & Cash Equivalents519.98M
Total Debt1.26B
Net Debt256.37M
Equity (Book Value)478.63M
Book Value Per Share1.37
Working Capital-1.49B

Cash Flow

After subtracting -79.64M in capital expenditures, free cash flow totaled -79.64M - equivalent to -0.23 per share.

Operating Cash FlowN/A
Capital Expenditures-79.64M
Free Cash Flow-79.64M
FCF Per Share-0.23

Margins

Hubei Guangji Pharmaceutical Co., Ltd. operates with a gross margin of 21.01, reflecting its pricing power and cost economics. The operating margin of -28.63 and net profit margin of -42.15 provide insight into operational efficiency.

Gross Margin21.01
Operating Margin-28.63
Pretax Margin-45.80
Profit Margin-42.15
EBITDA Margin-28.63

Dividends & Yields

The company's payout ratio of -17.80 indicates the proportion of earnings distributed to shareholders.

Dividend Per Share0.15
Dividend YieldN/A
Payout Ratio-17.80
Shareholder Yield0.25
FCF Yield3.69

Stock Splits

Hubei Guangji Pharmaceutical Co., Ltd.'s most recent stock split took place on May 29, 2020 with a 5:6 split ratio.

Last Split Date5/29/2020
Split Ratio5:6

Scores

Hubei Guangji Pharmaceutical Co., Ltd. posts an Altman Z-Score of 0.08, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.

Altman Z-Score0.08